Selank Nasal Spray: Intranasal Anxiolytic Peptide Research Overview

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a stabilized analog of the short tetrapeptide tuftsin (Thr-Lys-Pro-Arg) — a fragment of the immunoglobulin G heavy chain — extended with a Pro-Gly-Pro sequence. In research models, Selank has been studied for anxiolytic-like and cognitive effects, and the intranasal route is the standard administration route in both preclinical and clinical literature.

Structure and Origin

- Tuftsin analog: Tuftsin is a naturally occurring tetrapeptide with documented immunomodulatory activity in phagocyte research - Heptapeptide design: The added Pro-Gly-Pro tail improves stability against peptidases - No sedative mechanism: Unlike benzodiazepines, Selank does not act as a direct GABA receptor agonist — research instead describes GABAergic modulation and downstream effects

Intranasal Delivery Science

Selank was designed with intranasal use in mind, and this route is well suited to peptide research:

1. Direct nose-to-brain access: Neuropeptides administered intranasally can reach CNS tissue via olfactory and trigeminal routes, bypassing the blood-brain barrier 2. Rapid pharmacokinetics: Intranasal Selank reaches CNS compartments within minutes in animal studies 3. Degradation resistance: Intranasal administration avoids first-pass degradation, though Selank is still relatively short-acting compared to cyclic peptides

Research Findings

Selank is one of the better-studied nootropic peptides in the Russian-language and international pharmacology literature:

- Anxiolytic-like effects: In rodent models, Selank reduced anxiety-related behaviors on standard behavioral tests without sedation, muscle relaxation, or cognitive impairment - GABAergic interaction: Studies report Selank modulates GABA receptor function and alters the expression of GABA transporter genes — a benzodiazepine-like profile without direct receptor binding - BDNF and neuroplasticity: Selank administration increased BDNF and c-Fos expression in hippocampal and cortical regions in rodent studies - Enkephalin modulation: Selank inhibits enkephalin-degrading enzymes, potentially raising endogenous enkephalin levels - Immune interactions: Consistent with its tuftsin origin, Selank research also covers interleukin-6 modulation and antiviral immune markers

Research Protocol Reference

| Parameter | Typical Research Reference | |---|---| | Dose | 200-400 mcg (1-2 sprays) per administration | | Frequency | Once to three times daily | | Route | Intranasal | | Cycle | As-needed or continuous in research protocols | | Monitoring | Behavioral endpoints, cognitive testing batteries |

Research references commonly cite 200-400 mcg intranasal dosing one to three times daily in animal and early clinical studies.

Selank vs. Semax

Selank is frequently studied alongside Semax (ACTH 4-10 analog) as the two flagship Russian nootropic peptides:

| Property | Selank | Semax | |---|---|---| | Focus of research | Anxiety, emotional cognition | Cognition, neuroprotection, BDNF | | Primary signaling | GABAergic modulation, enkephalins | BDNF upregulation, dopamine/serotonin | | Structure | Tuftsin analog (7 aa) | ACTH 4-10 analog (7 aa with Pro-Gly-Pro tail) | | Route | Intranasal | Intranasal |

The two peptides share the Pro-Gly-Pro stabilizing tail but differ in their parent fragments and research profiles.

Handling and Quality

Research-grade Selank nasal spray should be stored refrigerated after opening, protected from heat and light, with verified: - HPLC purity verification (≥98%) - Certificate of Analysis with sequence confirmation - Verified peptide content per spray

*This article is for research and informational purposes only. Selank is sold for laboratory research purposes only and is not intended for human consumption. Not evaluated by the FDA.*